Farallon Capital Reporting Persons Acquire 5.2% Stake in BridgeBio Pharma, Inc.

On May 29, 2026, a group of reporting persons led by Farallon Capital Partners, L.P. and its affiliates filed a Schedule 13G regarding their holdings in BridgeBio Pharma, Inc. (BBIO). The filing reveals that the collective group of reporting persons, including various Farallon Funds and individual managers such as Joshua J. Dapice, Philip D. Dreyfuss, and Hannah E. Dunn, beneficially own an aggregate of 10,226,063 shares of Common Stock. This represents a 5.2% ownership stake in the company. The shares are held across multiple entities, with Farallon Healthcare Partners Master, L.P. holding the largest individual fund portion at 5,918,914 shares (3.0%). The reporting persons certified that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The event triggering this filing occurred on May 22, 2026. All individual reporting persons disclaim beneficial ownership of the reported shares except to the extent of their pecuniary interest therein.